As new infectious threats emerge worldwide, a key US health agency is quietly stepping away from language tied to pandemic planning.
Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver ...
Morning Overview on MSN
New nasal vaccine shields lungs for months from viruses, bacteria, and allergens
Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...
Dentists wrote more than 2.3 million prescriptions last year for an antibiotic called clindamycin, whose label has carried a ...
A new study has shed light on why patients with certain rare immune disorders develop severe, food-triggered allergic reactions while others with similar diagnoses do not. The findings, published in ...
Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results